Radiopharmaceuticals: molecular imaging using positron emission tomography.
暂无分享,去创建一个
[1] A. Wettstein. Fortschritte der Arzneimittelforschung , 1960, Experientia.
[2] M. Bergström,et al. Positron emission tomography (PET) in neuroendocrine gastrointestinal tumors. , 1993, Acta oncologica.
[3] S. Stone-Elander,et al. Preparation of 11C-labelled SCH 23390 for the in vivo study of dopamine D-1 receptors using positron emission tomography. , 1986, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.
[4] G. Antoni,et al. Effect of apomorphine infusion on dopamine synthesis rate relates to dopaminergic tone , 1998, Neuropharmacology.
[5] Obaidur Rahman,et al. [11C]Carbon monoxide, a versatile and useful precursor in labelling chemistry for PET‐ligand development , 2007 .
[6] Christer Halldin,et al. [18F]β-CIT-FP is superior to [11C]β-CIT-FP for quantitation of the dopamine transporter , 1997 .
[7] Roger T. Staff,et al. Single Photon Emission Computed Tomography (SPECT) , 2005 .
[8] J. Mazziotta,et al. Positron emission tomography and autoradiography: Principles and applications for the brain and heart , 1985 .
[9] Sylvain Houle,et al. Binding characteristics and sensitivity to endogenous dopamine of [11C]‐(+)‐PHNO, a new agonist radiotracer for imaging the high‐affinity state of D2 receptors in vivo using positron emission tomography , 2006, Journal of neurochemistry.
[10] S. Wessely,et al. Chronic fatigue syndrome: an update focusing on phenomenology and pathophysiology , 2006, Current opinion in psychiatry.
[11] Richard E. Carson,et al. Tracer Kinetic Modeling in PET , 2005 .
[12] M. Bergström,et al. Developments in PET for the detection of endocrine tumours. , 2005, Best practice & research. Clinical endocrinology & metabolism.
[13] W. Wadsak,et al. [18F]FETO: metabolic considerations , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[14] Yasuyoshi Watanabe,et al. Enzymatic Synthesis of Carboxy-11C-Labelled L-Tyrosine, L-DOPA, L-Tryptophan and 5-Hydroxy-L-tryptophan. , 1990 .
[15] M. Bergström,et al. Positron emission tomography with 5-hydroxytryprophan in neuroendocrine tumors. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] T Machii,et al. High uptake of [2-11C]acetyl-L-carnitine into the brain: a PET study. , 1997, Biochemical and biophysical research communications.
[17] B. Långström,et al. Amphetamine effects on dopamine release and synthesis rate studied in the Rhesus monkey brain by positron emission tomography , 2005, Journal of Neural Transmission.
[18] Yasuyoshi Watanabe,et al. Multi-enzymatic Synthesis of beta-11C-Labelled L-Tyrosine and L-DOPA. , 1990 .
[19] M. Bergström,et al. MAO-A inhibition in brain after dosing with esuprone, moclobemide and placebo in healthy volunteers: in vivo studies with positron emission tomography , 1997, European Journal of Clinical Pharmacology.
[20] T Greitz,et al. Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[21] K. Markides,et al. Supercritical fluid extraction of 11C-labeled metabolites in tissue using supercritical ammonia. , 1997, Analytical chemistry.
[22] C S Patlak,et al. Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[23] M. Bergström,et al. In vivo demonstration of enzyme activity in endocrine pancreatic tumors: decarboxylation of carbon-11-DOPA to carbon-11-dopamine. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[24] B. Långström,et al. Brain kinetics of L-[Β-11 C]DOPA in humans studied by positron emission tomography , 2005, Journal of Neural Transmission / General Section JNT.
[25] T Machii,et al. Acylcarnitine metabolism during fasting and after refeeding. , 1996, Biochemical and biophysical research communications.
[26] A. Nordberg,et al. Nicotine deposition and body distribution from a nicotine inhaler and a cigarette studied with positron emission tomography , 1996, Clinical pharmacology and therapeutics.
[27] Bengt Långström,et al. Pharmacokinetic studies with PET. , 2005, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.
[28] W. Vaalburg,et al. Rapid decar☐ylation of carbon-11 labelleddl-dopa in the brain: A potential approach for external detection of nervous structures , 1978, Brain Research.
[29] K. Gwinn‐Hardy,et al. The role of radiotracer imaging in Parkinson disease , 2005, Neurology.
[30] M. Bergström,et al. In vitro and in vivo primate evaluation of carbon-11-etomidate and carbon-11-metomidate as potential tracers for PET imaging of the adrenal cortex and its tumors. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[31] A. Carlsson,et al. 3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists , 1957, Nature.
[32] J. Rastad,et al. PET imaging of adrenal cortical tumors with the 11beta-hydroxylase tracer 11C-metomidate. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[33] Jonathan M. Links,et al. Imaging dopamine receptors in the human brain by positron tomography , 1983 .
[34] M. Häusser,et al. Kinetics of in vitro decarboxylation and the in vivo metabolism of 2-18F- and 6-18F-fluorodopa in the hooded rat. , 1988, Biochemical pharmacology.
[35] P. Hartvig,et al. A Comparison of 11C-Labeled l-DOPA and l-Fluorodopa as Positron Emission Tomography Tracers for the Presynaptic Dopaminergic System , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[36] C. Nahmias,et al. Dopamine visualized in the basal ganglia of living man , 1983, Nature.
[37] B. Långström,et al. Estimation of regional cerebral utilization of [11C]‐L‐3, 4‐dihydroxy‐phenylalanine (DOPA) in the primate by positron emission tomography , 1992, Acta neurologica Scandinavica.
[38] I. Francis,et al. Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. , 1999, Radiology.
[39] M. Bergström,et al. Blood–Brain Barrier Penetration of Zolmitriptan—Modelling of Positron Emission Tomography Data , 2006, Journal of Pharmacokinetics and Pharmacodynamics.
[40] Bengt Långström,et al. Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease , 1997, Annals of neurology.
[41] M. Bergström,et al. Distribution of Zolmitriptan into the CNS in Healthy Volunteers , 2005, Drugs in R&D.
[42] Christer Halldin,et al. [11C]β‐CIT‐FE, a radioligand for quantitation of the dopamine transporter in the living brain using positron emission tomography , 1996 .
[43] N. Volkow,et al. Selective reduction of radiotracer trapping by deuterium substitution: comparison of carbon-11-L-deprenyl and carbon-11-deprenyl-D2 for MAO B mapping. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[44] M. Bergström,et al. [11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. , 2006, The Journal of clinical endocrinology and metabolism.
[45] A. Nordberg,et al. Regional deposition of inhaled 11C‐nicotine vapor in the human airway as visualized by positron emission tomography , 1995, Clinical pharmacology and therapeutics.
[46] C. Patlak,et al. Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data. Generalizations , 1985, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[47] B. Långström,et al. In vivo evaluation of striatal dopamine reuptake sites using 11C‐nomifensine and positron emission tomography , 1987, Acta neurologica Scandinavica.
[48] B. Långström,et al. Liquid chromatographic analysis of brain homogenates and microdialysates for the quantification of L-[beta-11C]DOPA and its metabolites for the validation of positron emission tomography studies. , 1995, Journal of pharmaceutical and biomedical analysis.
[49] M. Bergström,et al. Distribution of Intranasal 11C-Zolmitriptan assessed by Positron Emission Tomography , 2005 .
[50] Olli Eskola,et al. [18F]FDOPA and [18F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease , 2001 .
[51] David W. Townsend,et al. Positon emission tomography: basic science and clinical practice , 2008 .
[52] W. Wadsak,et al. [18F]FETO for adrenocortical PET imaging: a pilot study in healthy volunteers , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[53] I. Gribbestad,et al. Nuclear magnetic resonance spectroscopy: biochemical evaluation of brain function in vivo and in vitro. , 1994, Neurotoxicology.
[54] D. Kuhl,et al. PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[55] K. Ishiwata,et al. PET tracers for imaging of the dopaminergic system. , 2006, Current medicinal chemistry.
[56] M. Bergström,et al. PET as a tool in the clinical evaluation of pituitary adenomas. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[57] M. Bergström,et al. Synthesis of some 11C-labelled MAO-A inhibitors and their in vivo uptake kinetics in rhesus monkey brain. , 1997, Nuclear medicine and biology.
[58] M. Bergström,et al. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography , 2003, Biological Psychiatry.
[59] G. Antoni,et al. Striatal kinetics of [11C]‐(+)‐nomifensine and 6‐[18F]fluoro‐L‐dopa in Parkinson's disease measured with positron emission tomography , 1990, Acta neurologica Scandinavica.
[60] H. Misaki,et al. Acylcarnitine deficiency in chronic fatigue syndrome. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[61] M. Bergström,et al. Positron emission tomography applied in the study of pituitary adenomas , 1991, Journal of endocrinological investigation.
[62] H. Engler,et al. Pheochromocytomas: detection with 11C hydroxyephedrine PET. , 2004, Radiology.
[63] B. Långström,et al. Cerebral uptake and utilization of therapeutic [β‐11C]‐L‐DOPA in Parkinson's disease measured by positron emission tomography. Relations to motor response , 1992, Acta neurologica Scandinavica.
[64] M. Bergström,et al. Positron emission tomography (PET) with 5-hydroxytryptophan (5-HTP) in the diagnosis and treatment follow upp of carcinoid tumors , 1998 .